Metabolic Acidosis Pipeline Insight 2025: Exploring Next-Generation Therapies to Restore Acid-Base Balance | DelveInsight

DelveInsight's "Metabolic Acidosis - Pipeline Insight, 2025" report offers a comprehensive analysis of the evolving therapeutic landscape for metabolic acidosis, a serious electrolyte disorder characterized by excessive acid accumulation in the body due to renal, gastrointestinal, or respiratory dysfunction. With growing awareness and clinical need, the pipeline is witnessing progress in both early-stage and late-stage drug development aimed at restoring systemic pH balance and improving renal and cardiovascular outcomes.

Current investigational therapies primarily target renal tubular acidosis, chronic kidney disease (CKD)-associated acidosis, and sepsis-induced metabolic acidosis, with companies focusing on mechanisms such as bicarbonate supplementation, proton buffering, anion exchange, and renal function preservation. Leading pipeline candidates include TRC101 (veverimer) by Tricida, which works by binding and removing hydrochloric acid in the gastrointestinal tract without adding sodium or bicarbonate, offering a novel non-absorbed polymer-based solution for CKD patients.

Other promising therapies are in development from companies like AstraZeneca, Renibus Therapeutics, and Reata Pharmaceuticals, aiming to address the underlying causes of acidosis or mitigate associated complications such as inflammation, oxidative stress, and bone demineralization. Additionally, combination strategies with CKD or heart failure drugs are being explored to enhance overall patient outcomes.

The report delves into each asset's mechanism of action, development phase, trial design, and regulatory status, while also identifying key clinical and commercial unmet needs. With metabolic acidosis linked to accelerated disease progression and poor quality of life, there is a growing push for innovative treatments that go beyond conventional sodium bicarbonate therapy.

As the pipeline matures, 2025 is set to be a pivotal year for redefining the management of metabolic acidosis-particularly in CKD and critically ill populations-ushering in more effective and patient-centric therapeutic options.

Interested in learning more about the current treatment landscape and the key drivers shaping the metabolic acidosis pipeline? Click here: https://www.delveinsight.com/report-store/metabolic-acidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Metabolic Acidosis Pipeline Report
• DelveInsight's metabolic acidosis pipeline analysis depicts a strong space with 5+ active players working to develop 5+ pipeline drugs for metabolic acidosis treatment.
• The leading metabolic acidosis companies include Ardelyx, Tricida, Haim Bio, Pharmazz, and others are evaluating their lead assets to improve the metabolic acidosis treatment landscape.
• Key metabolic acidosis pipeline therapies in various stages of development include RDX020, Veverimer (TRC101), Aldehyde dehydrogenase inhibitor, PMZ 2123, and others.
• In February 2025, Milla Pharmaceuticals, through its U.S. subsidiary, received FDA approval for a generic version of Hospira's THAM Solution Tromethamine Injection 18GM/500ml, which is indicated for the prevention and correction of metabolic acidosis.

Request a sample and discover the recent breakthroughs happening in the metabolic acidosis pipeline landscape at https://www.delveinsight.com/report-store/metabolic-acidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Metabolic Acidosis Overview
Metabolic acidosis is characterized by a primary decrease in bicarbonate levels, often accompanied by a compensatory drop in carbon dioxide partial pressure, leading to excessive acidity in the blood. It can result from various conditions such as kidney failure, poisoning, and shock. Common symptoms include nausea, vomiting, lethargy, and rapid breathing (hyperpnea). The condition arises through three main mechanisms: increased acid production, loss of bicarbonate, or reduced renal acid excretion. Diagnosis involves clinical evaluation along with arterial blood gas (ABG) analysis and serum electrolyte testing. Currently, there are no FDA-approved treatments for long-term management of metabolic acidosis; therapy focuses on addressing the underlying cause, with alkali therapy and dietary changes used to help restore acid-base balance.

Find out more about metabolic acidosis medication at https://www.delveinsight.com/report-store/metabolic-acidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Metabolic Acidosis Treatment Analysis: Drug Profile
Veverimer (TRC101): Tricida
Veverimer (TRC101), developed by Tricida, is an oral, non-absorbed polymer designed to treat metabolic acidosis in chronic kidney disease (CKD) patients. It works by binding hydrochloric acid in the gastrointestinal tract, which is then eliminated through fecal excretion. Veverimer is currently in Phase III clinical trials to assess its impact on CKD progression and to evaluate its safety in CKD patients with metabolic acidosis.

Learn more about the novel and emerging metabolic acidosis pipeline therapies at https://www.delveinsight.com/report-store/metabolic-acidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Metabolic Acidosis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Metabolic Acidosis Pipeline Report
• Coverage: Global
• Key Metabolic Acidosis Companies: Ardelyx, Tricida, Haim Bio, Pharmazz, and others.
• Key Metabolic Acidosis Pipeline Therapies: RDX020, Veverimer (TRC101), Aldehyde dehydrogenase inhibitor, PMZ 2123, and others.

To dive deep into rich insights for drugs used for metabolic acidosis treatment, visit: https://www.delveinsight.com/report-store/metabolic-acidosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Metabolic Acidosis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Metabolic Acidosis Pipeline Therapeutics
6. Metabolic Acidosis Pipeline: Late-Stage Products (Phase III)
7. Metabolic Acidosis Pipeline: Mid-Stage Products (Phase II)
8. Metabolic Acidosis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.